Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for Th1 induction and dendritic cell activation

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 3045-3052

  Mesa, Circe ^a   De León, Joel ^a   Rigley, Kevin ^b   Fernández, Luis E ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b EDWARD JENNER INST FOR VACC RES   (United Kingdom)

Author keywords

Dendritic cells; Neisseria meningitidis; Th1 Th2 cells

Indexed keywords

IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG EFFECT; FLUORESCENCE ACTIVATED CELL SORTING; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOLIPOSOME; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; BONE MARROW CELLS; CELL DIVISION; CELLS, CULTURED; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; INDICATORS AND REAGENTS; INTERLEUKIN-12; LIPOSOMES; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C3H; NEISSERIA MENINGITIDIS; NUCLEASE PROTECTION ASSAYS; OVALBUMIN; PARTICLE SIZE; TH1 CELLS;

EID: 3843071048     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.010     Document Type: Article

References (31)

1. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:1994;991-1045
2. Jeannin P., Renno T., Goetsch L., Miconnet I., Aubry J.P., Delneste Y., et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat. Immunol. 6:2000;502-509
3. Hartmann G., Weiner G.J., Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 96:1999;9305-9310
4. Kolb-Maurer A., Unkmeir A., Kammerer U., Hubner C., Leimbach T., Stade A., et al. Interaction of Neisseria meningitidis with human dendritic cells. Infect. Immun. 69:2001;6912-6922
5. Dixon G.L.J., Newton P.J., Chain B.M., Katz D., Andersen S.R., Wong S., et al. Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: IL-12 production requires lipopolysaccharide to be expressed in intact bacteria. Infect. Immunol. 69:2001;4351-4357
6. Andersen B.M. Endotoxin releases from Neisseria meningitidis. Relationship between key bacterial characteristics and meningococcal disease. Scand. J. Infect. Dis. Suppl. 64:1989;1-43
7. Lowell GH. Proteosomes, hydrophobic anchors, ISCOMS and liposomes for improved presentation of peptide and protein vaccines. In: Woodrow GC, Levine MM, editors. New generation vaccines. Marcel Dekker: NY; 1990. p. 141-60.
8. Zollinger WD. New and improved vaccines against meningococcal disease. In: Woodrow GC, Levine MM, editors. New generation vaccines. Marcel Dekker: NY; 1990. p. 325-48.
9. Arigita C., Bevaart L., Everse L.A., Koning G.A., Hennink W.E., Crommelin D.J., et al. Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response. Infect. Immun. 71:2003;5210-5218
10. Estevez F., Carr A., Solorzano L., Valiente O., Mesa C., Barroso O., et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine. 18:1999;190-197
11. Carr A., Estevez F., Mazorra Z., Mesa C., Valiente O., Perez R., et al. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res. 3:2001;219-227
12. Carr A., Rodríguez E., Arango M., Camacho R., Osorio M., Gabri M., et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J. Clin. Oncol. 21:2003;1015-1021
13. Aucouturier J., Dupuis L., Deville S., Ascarateil S., Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines. 1:2002;111-118
14. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large amounts of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1992;1693-16702
15. Zhou Z.H., Wang J.F., Wang Y.D., Qiu Y.H., Pan J.Z., Xie W., et al. An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of myeloma cell line. Hybridoma. 18:1999;471-478
16. Paluka C., Banchereau J. Dendritic cells: a link beteween innate and adaptive immunity. J. Clin. Immunol. 9:1999;12-25
17. Dabbagh K., Lewis D.B. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr. Opin. Infect. Dis. 16:2003;199-204
18. Khoruts A., Mondino A., Pape K.A., Reiner S.L., Jenkins M.K. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J. Exp. Med. 187:1998;225-236
19. Johnson A.G., Tomai M., Solem L., Beck L., Ribi E. Characterization of a nontoxic monophosphoryl lipid A. Infect. Dis. 9:1987;512-516
20. Tholen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., et al. Safety and immunegenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 16:1998;708-714
21. Pulendran B., Smith J.L., Caspary G., Brasel K., Pettit D., Maraskovsky E., et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. U.S.A. 96:1999;1036-1041
22. Maldonado Lopez R., De Smedt T., Michel P., Godfroid J., Pajak B., Heirman C., et al. CD8α+ and CD8α-: subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189:1999;587-592
23. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13:2001;114-119
24. Whelan M., Harnett M.M., Houston K.M., Patel V., Harnett W., Rigley K. A filarial nematode-secreted product signals dendritic cells to acquire a phenotype that drives development of Th2 cells. J. Immunol. 164:2000;6453-6460
25. Macatonia S.E., Hosken N.A., Litton M., Vieira P., Hsieh C.S., Culpepper J.A., et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J. Immunol. 154:1995;5071-5079
26. Kadowaki N., Antonenko S., Liu Y.J. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol. 166:2001;2291-2295
27. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., et al. The interleukin-12/interleukin-12 receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16:1998;495-521
28. Stoll S., Jonuleit H., Schmitt E., Muller G., Yamauchi H., Kurimoto M., et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12 dependent Th1 development. Eur. J. Immunol. 28:1998;3231-3239
29. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 299:2003;1033-1036
30. Poltorak A., He X., Smirnova I., Liu M., Van V., Huffel X., et al. Defective LPS signaling in C3H/HeJ and C57Bl/10ScCr mice: mutations in Tlr4 gene. Science. 282:1998;2085-2088
31. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., et al. The repertoire for pattern recognition of pathogens by the innate system is defined by cooperation between Toll-like receptors. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13766-13771